Aims: To evaluate slow-release oral morphine (SROM) as an alternative maintenance pharmacotherapy to methadone for treatment of opioid dependence.
Design: Open-label crossover study.
Setting: Out-patient methadone maintenance programme.
Participants: Eighteen methadone maintenance patients. Intervention Participants were transferred from methadone to SROM (once-daily Kapanol trade mark ) for approximately 6 weeks before resuming methadone maintenance.
Measurements: Patient outcomes were assessed (1) during the transition between medications (dose requirements, withdrawal severity) and (2) after at least 4 weeks on a stable dose of each drug (treatment preference, patient ratings of treatment efficacy and acceptability, drug use, health, depression and sleep).
Findings: Transfer from methadone to SROM was associated with relatively mild withdrawal for the first 5 days; the final mean SROM : methadone dose ratio was 4.6 : 1. Compared to methadone, SROM was associated with improved social functioning, weight loss, fewer and less troublesome side-effects, greater drug liking, reduced heroin craving, an enhanced sense of feeling 'normal' and similar outcomes for unsanctioned drug use, depression and health. The majority of subjects preferred SROM (78%) over methadone (22%).
Conclusions: These findings provide justification for further evaluation of SROM as a maintenance pharmacotherapy for opioid dependence.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1360-0443.2004.00764.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Navigating new norms: Addiction specialists' perspectives on opioid use disorder treatments and policy challenges in the fentanyl era.
Am J Addict
January 2025
Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA.
Article Synopsis
- The study examines the impact of high-potency synthetic opioids (HPSOs) on addiction treatment, with a focus on how they affect the prescribing practices of addiction specialists in the USA.
- Findings reveal that a significant majority of addiction specialists (89%) believe HPSOs have influenced treatment protocols, with 84% seeing a need for additional opioid agonist therapies beyond methadone.
- The study highlights a strong support (80%) among specialists for using slow-release oral morphine (SROM) as a potential new treatment option for opioid use disorder (OUD) in response to the growing crisis.
Prescribing practices in opioid agonist treatment and changes in compliance to clinical dosing guidelines in British Columbia, Canada.
Addiction
August 2024
Centre for Advancing Health Outcomes, Vancouver, British Columbia, Canada.
Background And Aim: In British Columbia, Canada, clinical guidelines for the treatment of opioid use disorders (OUD) were updated in 2017, during a period in which the potency and composition of the illicit drug supply changed rapidly. We aimed to describe changes in opioid agonist treatment (OAT) prescribing practices at the population level in a setting in which fentanyl and its analogs have become the primary illicit opioid of use.
Design, Setting And Participants: This was a population-based retrospective cohort study using three linked health administrative databases in British Columbia (BC), Canada.
Initiation and rapid titration of methadone and slow-release oral morphine (SROM) in an acute care, inpatient setting: a case series.
Eur J Med Res
December 2023
Department of Family & Community Medicine, University of Toronto, Toronto, Canada.
Background: Methadone titration in an outpatient setting typically involves initiation with subtherapeutic doses with slow titration to mitigate the risks of respiratory depression and overdose. In pregnancy, and generally, subtherapeutic doses of methadone and slow titrations are associated with poorer outcomes in terms of treatment retention and ongoing illicit opioid use. We aim to describe rapid titration of OAT in an inpatient setting for pregnant injection opioid users with high opioid tolerance secondary to a fentanyl-based illicit drug supply.
View Article and Find Full Text PDFOutpatient Rapid Titration of Slow Release Oral Morphine for the Treatment of Opioid Use Disorder in a Canadian Setting: A Case Series.
J Addict Med
November 2023
From the British Columbia Centre on Substance Use, Vancouver, BC, Canada (OB, SI); Department of Medicine, University of British Columbia, St. Paul's Hospital, 1081 Burrard Street, Vancouver, BC, Canada (OB, SI); Providence Health Care, Vancouver, BC, Canada (JCYN); and Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada (JCYN).
Introduction: In the midst of unprecedented opioid overdose deaths, opioid agonist therapy induction strategies that allow for rapid titration to therapeutic doses for individuals at high risk of overdose are needed. Slow release oral morphine (SROM) is an effective treatment for opioid use disorder; however, current guideline-recommended titration strategies require weeks to achieve therapeutic dose for individuals with high opioid tolerance. Individuals may be lost to care or experience overdose due to ongoing use of unregulated opioids during this time.
View Article and Find Full Text PDFCharacterizing opioid agonist therapy uptake and factors associated with treatment retention among people with HIV in British Columbia, Canada.
Prev Med Rep
October 2023
British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada.
Accidental overdoses are now the leading cause of death among people with HIV (PWH) in British Columbia (BC). We examined the utilization and retention of opioid agonist therapy (OAT). Adult PWH (≥19 years) with ≥ 1 OAT dispensation in BC between 2008 and 2020 were included (n = 1,515).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!